Zimmer rated a "buy" after spin-off:
This article was originally published in Clinica
Analyst JP Morgan has given Zimmer a "buy" rating, with a 12-month target of $34. The orthopaedics company, which has just been spun-off from Bristol-Myers Squibb, is trading at just under $30.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.